Welcome to our dedicated page for The Beauty Health Company news (Ticker: SKIN), a resource for investors and traders seeking the latest updates and insights on The Beauty Health Company stock.
The Beauty Health Company (NASDAQ: SKIN) generates a steady flow of news at the intersection of medical technology, professional aesthetics, and beauty. As the parent of Hydrafacial, SkinStylus, and Keravive, the company issues regular updates on financial performance, science-backed innovation, provider partnerships, and corporate governance, giving investors and industry followers insight into how its skin health platform is evolving.
On this page, readers can follow earnings announcements and financial results, where BeautyHealth reports net sales, gross margin, adjusted EBITDA, delivery systems sold, and active install base across the Americas, Asia-Pacific, and EMEA. These releases often include management commentary on trends in device sales versus consumables, the performance of the recurring revenue stream, and changes in regional go-to-market strategies.
News coverage also highlights product and innovation updates, such as the launch of boosters like HydraFillic with Pep9 and references to Hydralock HA Booster, as well as insights from the company’s Skintuition Report, which explores consumer trends in modern skin health and aesthetics. Additional stories focus on initiatives like the Hydrafacial Advisory Councils and Ambassador Network, which bring together plastic surgeons, dermatologists, aesthetic practitioners, and estheticians to guide product development, education, and clinical research.
Corporate and governance news includes executive appointments, board changes, and capital structure developments, such as the appointment of a new President and Chief Executive Officer, the addition of a new independent director, and updates related to convertible senior notes and charter amendments. For anyone tracking SKIN, this news feed offers a centralized view of the company’s operational progress, strategic priorities, and role in professional skin and scalp health.
BeautyHealth (NASDAQ: SKIN) reported full year and Q4 2025 results with improved profitability and tighter costs despite lower equipment sales. 2025 net sales were $300.8M vs $334.3M in 2024; gross margin rose to 65.3% from 54.5% and adjusted EBITDA improved to $45.1M from $12.3M.
The company placed 3,726 delivery systems in 2025 (down from 4,907) and ended the year with ~$233M cash after repurchasing convertible notes; 2026 guidance targets $285–$305M net sales and $35–$45M adjusted EBITDA.
BeautyHealth (NASDAQ: SKIN) announced expanding adoption of its Hydrafacial and SkinStylus Nano-Channeling combination protocol across U.S. aesthetic and wellness providers, citing rising demand for combination treatments that deliver enhanced results with no downtime. The company highlighted provider adoption, a LifeSpa rollout, and survey data showing broad consumer and provider support for combination therapies.
BeautyHealth (NASDAQ:SKIN) will report Q4 and full-year 2025 financial results after market close on March 12, 2026.
The company will host an investor conference call at 4:30 p.m. ET the same day with a live webcast and supporting materials on https://investors.beautyhealth.com. A recording will be available about three hours after the call concludes.
BeautyHealth (NASDAQ: SKIN) released Skintuition Report: Volume Three on December 4, 2025, profiling consumer shifts toward skin regeneration over correction.
Key metrics: 75% of consumers now prioritize treatments that improve overall skin quality; Hydrafacial reports an average of 3.6 treatments per year per client and 50% of clients purchase an add-on treatment or retail product during visits. The company highlights the June 2025 launch of the HydraFillic with Pep9 Booster and cites a clinical study showing measurable improvements 24 hours after treatment in 30 participants.
BeautyHealth (NASDAQ: SKIN) reported Q3 2025 results for the quarter ended September 30, 2025. Net sales were $70.7M, down (10.3)% year‑over‑year. Gross margin improved to 64.6% from 51.6% a year ago, and adjusted gross margin was 68.0%. Net loss narrowed to $(11.0)M and Adjusted EBITDA rose to $8.9M from $8.1M. The company placed 875 delivery systems (vs. 1,118 prior year) and reported an active install base of 35,409. Cash and equivalents were approximately $219M as of September 30, 2025. Fiscal 2025 guidance was updated to $293–$300M net sales and $37–$39M adjusted EBITDA.
BeautyHealth (NASDAQ: SKIN) appointed Philippe Schaison, PharmaD to its Board of Directors, effective October 30, 2025. Schaison brings over 20 years of leadership across global aesthetics, biotech, and consumer health, including roles as CEO NA of Syneron Candela and President of Allergan Aesthetics, and current CEO of Soltégo, Inc.
He will join the Compensation and Nominating & Corporate Governance Committees. Following the appointment, the Board will total eight directors. The company said Schaison’s experience should help expand Hydrafacial’s global reach and accelerate category growth.
Beauty Health (NASDAQ:SKIN) will report third quarter 2025 financial results after market close on Thursday, November 6, 2025. The company will host an investor conference call at 4:30 p.m. Eastern Time following a press release that details the results.
A live webcast and supporting materials will be available on the company investor relations website at https://investors.beautyhealth.com. A recording of the call will be posted approximately three hours after the call concludes. The company discloses material information via SEC filings, press releases, public calls, and its investor relations website to comply with Regulation FD.
The Beauty Health Company (NASDAQ: SKIN) has appointed Pedro Malha as its new President and Chief Executive Officer, effective October 1, 2025. Malha, who brings over 20 years of experience in healthcare and medical devices, succeeds Marla Beck, who is stepping down but will remain in an advisory role.
Malha joins from Abbott Laboratories, where he served as Worldwide Division President and Corporate Officer leading the neuromodulation business. His prior experience includes senior leadership roles at Zimmer Biomet Holdings, Abbott, and Johnson & Johnson in Europe.
Under Beck's leadership, BeautyHealth underwent significant transformation, including strengthening its innovation pipeline, upgrading manufacturing and operations, improving margins, and maintaining Hydrafacial's position as a leading performance skin health brand.
BeautyHealth's (NASDAQ: SKIN) flagship brand Hydrafacial has achieved a significant milestone by entering Cosmopolitan's Readers' Choice Hall of Fame after winning Best Pro Facial for the third time. The company has garnered multiple prestigious awards in 2025, including recognition from ELLE, NewBeauty, and Good Housekeeping.
Hydrafacial demonstrates strong market leadership with 38% brand awareness and a global social media following of 1.3 million. The treatment's effectiveness is reflected in consumer loyalty, with 92% of clients stating they would switch estheticians if Hydrafacial treatments weren't available. The brand maintains the highest online engagement among aesthetic peers, driving client demand and provider growth.
The Beauty Health Company (NASDAQ:SKIN) has launched the Hydrafacial Advisory Councils and Ambassador Network, bringing together leading plastic surgeons, dermatologists, aesthetic practitioners, and estheticians to guide the company's future development.
The initiative aims to enhance product innovation, education programs, and clinical research through real-world insights. The councils will be led by three inaugural chairs: Ted Lain, MD, MBA; Blaklee Paige Smith, MSN, APRN; and Kelly Horton-Beeman, LE.
This strategic move builds upon Hydrafacial's existing professional development initiatives, including their HFX Training Programs which have trained over 60,000 providers globally. The company also maintains partnerships with various professional organizations and offers scholarship programs for estheticians.